Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential ‘nocebo’ effect, insisted Professor Fabrizio Benedetti at a EULAR symposium.
Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential adverse consequences of the ‘nocebo’ effect, according to Professor Fabrizio Benedetti of the department of neuroscience within Italy’s University of Turin.
Speaking at a European League Against Rheumatism (EULAR) virtual symposium on real-world evidence on the subject of “effective communication in...
Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.
Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.
The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.
